Immunovant will discontinue development of imeroprubart in cutaneous lupus erythematosus after the phase 2b study failed to meet its primary endpoint.
|Videos|February 22, 2022
Study into New Possible Treatment of Sturge Weber Syndrome
Author(s)Linda Stocum, Associate Editor
A recent mouse model study on the efficacy of using imatinib as a treatment for Sturge Weber Syndrome has been published. In this video interview we talk with one of the investigators, Jack L. Arbiser, MD, PhD, on what the results means for future clinical trials.
Advertisement
A link to the article is available
Advertisement
Related to this article
Both barzolvolimab doses improved UAS7 at week 12 in EMBARQ-CSU1 and EMBARQ-CSU2, with up to 54% of patients reaching complete response by week 24.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.
Sol-Gel Technologies has completed patient follow-up in its pivotal phase 3 trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, with top-line results expected in late November 2026.
Two small clinical studies evaluated skincare and dermabrasion for changes in skin quality among individuals taking medical weight loss medications.
The FDA has set a PDUFA target action date of June 29, 2027, based on APEX trial data showing a 65% overall response rate in advanced systemic mastocytosis.
The expanded indication makes Ameluz with RhodoLED the first FDA-approved photodynamic therapy for the treatment of a skin cancer.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Grants Fast Track Designation to QRX003 for Peeling Skin Syndrome
2
Barzolvolimab Achieves All Phase 3 End Points in Chronic Spontaneous Urticaria
3
Don't Be Rash: Building the Pediatric Psoriasis Treatment Ladder
4
Alopecia Awareness Month: Supporting Patients Beyond the Treatment Plan
5